Leukoreduction: Difference between revisions
CSV import Tag: Reverted |
No edit summary Tag: Manual revert |
||
| Line 25: | Line 25: | ||
{{Medicine-stub}} | {{Medicine-stub}} | ||
{{No image}} | {{No image}} | ||
Latest revision as of 18:41, 18 March 2025
Leukoreduction is a medical procedure that reduces the number of white blood cells (leukocytes) in a blood sample. It is commonly used in blood transfusion services to minimize the risk of certain complications associated with transfusion.
Overview[edit]
Leukoreduction is performed on blood products such as packed red blood cells and platelet concentrates before they are transfused into patients. The process involves passing the blood product through a filter designed to remove leukocytes. This is typically done in the blood bank after the blood has been collected from a donor but before it is stored in the blood bank inventory.
Benefits[edit]
The primary benefit of leukoreduction is the reduction in the risk of febrile non-hemolytic transfusion reactions (FNHTR), which are caused by the body's immune response to leukocytes in the transfused blood. Leukoreduction also reduces the risk of Human Leukocyte Antigen (HLA) alloimmunization, a condition in which the recipient's immune system develops antibodies against the donor's leukocytes, and Transfusion Associated Graft Versus Host Disease (TA-GVHD), a rare but serious complication of blood transfusion.
Risks[edit]
While leukoreduction has many benefits, it is not without risks. The process can lead to a slight reduction in the number of red blood cells and platelets in the blood product, which may affect its efficacy. There is also a small risk of contamination during the process.
